Proper application of anticoagulation therapy on cancer‑associated venous thrombosis
10.1007/s44313-024-00029-3
- Author:
Ho‑Young YHIM
1
Author Information
1. Department of Internal Medicine, Jeonbuk National University Medical School, 20 Geonji‑Ro, Deokjin‑Gu, Jeonju 54907, Republic of Korea
- Publication Type:REVIEW
- From:Blood Research
2024;59():25-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cancer-associated venous thromboembolism (VTE) significantly impacts morbidity and mortality. The introduction of direct oral anticoagulants over the past decade has revolutionized VTE treatment in patients with active cancer, offering potential advantages over traditional therapies. However, uncertainties persist regarding the optimal selec‑ tion and dosage of anticoagulants, particularly in patients with specific risk factors for bleeding, such as certain cancer types (e.g., upper gastrointestinal cancer, genitourinary cancer, primary or metastatic brain tumor, and hematologic malignancies) and specific patient characteristics (e.g., renal dysfunction and thrombocytopenia). Recent data on the thrombotic risk associated with low thrombotic burden VTE, such as subsegmental pulmonary embolism and isolated distal deep vein thrombosis, underscore the need for updated management strategies in daily clini‑ cal practice. This review aims to explore these issues and highlight the evolving landscape of cancer-associated VTE management.
